Have a feature idea you'd love to see implemented?
Let us know!
BDSX Biodesix Inc
Price (delayed)
$1.58
Market cap
$229.38M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.45
Enterprise value
$248.78M
Biodesix, Inc. operates as a biotechnology company. The Company offers non-small cell lung cancer pretreatment serum tests and laboratory testing. Biodesix provides diagnostic tools and equipment for blood and tissue
Highlights
The company's gross profit has surged by 67% YoY and by 13% QoQ
BDSX's EPS has soared by 58% year-on-year and by 17% since the previous quarter
BDSX's debt is up by 37% YoY
Key stats
What are the main financial stats of BDSX
Market
Valuations
Earnings
Shares outstanding
145.18M
Market cap
$229.38M
Enterprise value
$248.78M
Price to earnings (P/E)
N/A
Price to book (P/B)
5
Price to sales (P/S)
3.3
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.08
Revenue
$60.9M
EBIT
-$35.33M
EBITDA
-$30.15M
Free cash flow
-$61.16M
Per share
Balance sheet
Liquidity
EPS
-$0.45
Free cash flow per share
-$0.48
Book value per share
$0.32
Revenue per share
$0.48
TBVPS
$0.74
Total assets
$115.84M
Total liabilities
$79.58M
Debt
$61.62M
Equity
$36.26M
Working capital
$40.03M
Debt to equity
1.7
Current ratio
3.28
Quick ratio
2.98
Net debt/EBITDA
-0.64
Margins
Efficiency
Dividend
EBITDA margin
-49.5%
Gross margin
77.6%
Net margin
-73.1%
Operating margin
-54.7%
Return on assets
-45.8%
Return on equity
-525.3%
Return on invested capital
-44.5%
Return on capital employed
-35.9%
Return on sales
-58%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BDSX stock price
How has the Biodesix stock price performed over time
Intraday
-1.86%
1 week
-4.82%
1 month
-0.63%
1 year
-1.25%
YTD
-14.13%
QTD
-11.24%
Financial performance
How have Biodesix's revenue and profit performed over time
Revenue
$60.9M
Gross profit
$47.25M
Operating income
-$33.3M
Net income
-$44.51M
Gross margin
77.6%
Net margin
-73.1%
The company's gross profit has surged by 67% YoY and by 13% QoQ
The operating margin has surged by 56% year-on-year and by 17% since the previous quarter
BDSX's net margin has soared by 54% YoY and by 15% QoQ
Biodesix's revenue has increased by 46% YoY and by 11% QoQ
Growth
What is Biodesix's growth rate over time
Valuation
What is Biodesix stock price valuation
P/E
N/A
P/B
5
P/S
3.3
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.08
BDSX's EPS has soared by 58% year-on-year and by 17% since the previous quarter
Biodesix's revenue has increased by 46% YoY and by 11% QoQ
The price to sales (P/S) is 16% higher than the last 4 quarters average of 2.9
Efficiency
How efficient is Biodesix business performance
BDSX's ROIC has soared by 71% YoY and by 18% QoQ
The ROE has soared by 70% YoY
BDSX's ROS has soared by 57% year-on-year and by 15% since the previous quarter
BDSX's return on assets is up by 46% year-on-year and by 15% since the previous quarter
Dividends
What is BDSX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BDSX.
Financial health
How did Biodesix financials performed over time
The company's total assets is 46% higher than its total liabilities
The company's total assets rose by 49% YoY and by 33% QoQ
The total liabilities has declined by 14% since the previous quarter and by 6% year-on-year
BDSX's debt is 70% higher than its equity
The debt to equity has soared by 126% year-on-year and by 115% since the previous quarter
BDSX's debt is up by 37% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.